Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions

Beatrice Y Brewington,1 Yusra F Shao,2 Fredrick H Davidorf,1 Colleen M Cebulla1 1Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University, 2Medical Student Research Program, The Ohio State University College of Medicine, Columbus, OH, USA Abstract: Surgical mana...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Brewington BY, Shao YF, Davidorf FH, Cebulla CM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
UM
Acceso en línea:https://doaj.org/article/6e561f2eeb344cf4840e1afb31c130af
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Beatrice Y Brewington,1 Yusra F Shao,2 Fredrick H Davidorf,1 Colleen M Cebulla1 1Havener Eye Institute, Department of Ophthalmology and Visual Science, Ohio State University, 2Medical Student Research Program, The Ohio State University College of Medicine, Columbus, OH, USA Abstract: Surgical management with enucleation was the primary treatment for uveal melanoma (UM) for over 100 years. The Collaborative Ocular Melanoma Study confirmed in 2001 that globe-preserving episcleral brachytherapy for UM was safe and effective, demonstrating no survival difference with enucleation. Today, brachytherapy is the most common form of radiotherapy for UM. We review the history of brachytherapy in the treatment of UM and the evolution of the procedure to incorporate fine-needle-aspiration biopsy techniques with DNA- and RNA-based genetic prognostic testing. Keywords: brachytherapy, uveal melanoma, UM, fine-needle-aspiration biopsy, genetic prognostic testing, molecular markers